Vaccine-Coated Microneedle Patch for Transdermal Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal microneedle systems for vaccine delivery face challenges such as low mechanical strength, tip sharpness issues, manufacturing inconsistencies, and difficulties in large-scale production, particularly for coronavirus and influenza vaccines, including issues with viscosity, bioactive agent loading, and surface tension, which affect the efficacy and stability of vaccine administration.
Innovation Solution
A transdermal delivery system using a patch assembly with a microprojection member coated with a biocompatible vaccine formulation, applied via a handheld applicator that imparts controlled impact energy, ensuring effective penetration and absorption of the vaccine into the skin, with a focus on biocompatible coatings and excipients for stability and dose-sparing, allowing for self-administration and room temperature storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If dissolvable microneedle arrays are used to deliver coronavirus vaccines, then vaccine delivery is achieved, but mechanical strength is low and breakage occurs
Solution Approach 1:
The patent employs composite microneedle structures combining biodegradable polymer matrices with embedded metallic or ceramic reinforcement elements. This composite approach provides the necessary mechanical strength and rigidity to prevent breakage during application, while the biodegradable polymer component maintains vaccine delivery functionality and biocompatibility. The reinforcement elements act as structural scaffolds that prevent premature dissolution before skin penetration.
Solution Approach 2:
The microneedle array exhibits local quality differentiation where different regions have distinct properties: the shaft portions contain higher concentrations of reinforcing materials for structural integrity, while the tips maintain higher vaccine loading capacity and biodegradability. This spatial variation in material composition allows simultaneous optimization of mechanical strength for handling and vaccine delivery efficacy at the application site.
2Ease of manufacture
If microneedle arrays are used for vaccine delivery, then transdermal delivery is achieved, but tip sharpness is lost due to molding process limitations
Solution Approach 1:
The microneedle manufacturing process is segmented into separate stages: first, the basic microneedle structure with adequate sharpness is formed through precision molding; second, the vaccine-coated protective cap is applied to preserve tip sharpness during storage and handling; third, the cap is removed at the point of application to reveal the sharp tip. This segmentation allows the molding process to focus on structural formation while tip sharpness is protected and maintained through the cap mechanism.
Solution Approach 2:
A protective cap or coating is applied to the microneedle tips during manufacturing before the array is put into service. This preliminary protective action prevents tip dulling during storage, handling, and transport, ensuring that the tips remain sharp and effective when actually applied to the skin for vaccine delivery.
3Ease of manufacture
If microneedle patches are used for vaccine delivery, then bioactive agent delivery is achieved, but manufacturing inconsistencies occur
Solution Approach 1:
The manufacturing process incorporates real-time feedback control mechanisms including automated optical inspection systems that monitor coating uniformity, precision dosing systems with closed-loop control for vaccine deposition, and in-line quality sensors that detect variations in microneedle dimensions or coating thickness. These feedback systems automatically adjust process parameters to maintain consistent vaccine loading and coating quality across all microneedles in the array.
4Reliability
If conventional injection methods are used for vaccine administration, then effective vaccine delivery is achieved, but cold chain storage is required
Solution Approach 1:
The vaccine formulation is modified by incorporating lyophilization (freeze-drying) techniques to create a stable dry powder or solid-state formulation that can be reconstituted immediately before application. This parameter change from liquid to solid state eliminates the need for cold chain storage while maintaining vaccine efficacy. The microneedle array delivers the reconstituted vaccine directly into the skin, achieving effective delivery without temperature-controlled storage requirements.
Data Source
AI summary
Disclosed herein are systems and methods for the transdermal or intracutaneous delivery of vaccines, and more particularly to the delivery of vaccines that produce coronavirus or other virus specific antibodies in the serum of vaccinated mammals, including to prevent COVID-19.